UroGen Pharma
URGN
84 hedge funds and large institutions have $382M invested in UroGen Pharma in 2020 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 17 reducing their positions, and 8 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 17
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
53% more capital invested
Capital invested by funds: $250M → $382M (+$132M)
6% more funds holding
Funds holding: 79 → 84 (+5)
0.61% more ownership
Funds ownership: 66.27% → 66.88% (+0.61%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less call options, than puts
Call options by funds: $5.93M | Put options by funds: $7.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.1M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.97M |
| 3 |
HCM
Horton Capital Management
Philadelphia,
Pennsylvania
|
+$3.22M |
| 4 |
Millennium Management
New York
|
+$2.6M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$12M |
| 2 |
HCM
Highline Capital Management
New York
|
-$3.97M |
| 3 |
PC
Pier Capital
Stamford,
Connecticut
|
-$2.68M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$2.61M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.13M |
URGN Hedge Fund Activity: Q2 2020 in Review
84 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2020, worth a combined $382M — up 53% from $250M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new URGN positions and 8 closed out — a net gain of 5 holders — while 39 added to existing stakes and 17 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $22.1M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $12M sold.
- 84 institutional investors held UroGen Pharma (URGN) as of Q2 2020, up from 79 in Q1 2020.
- Funds reported $382M of UroGen Pharma stock for Q2 2020, up 53% quarter-over-quarter.
- 13 funds opened new UroGen Pharma positions in Q2 2020 and 8 closed out, a net change of +5 holders.
- The largest UroGen Pharma buyer in Q2 2020 was Wellington Management Group, an estimated $22.1M added.
- The largest UroGen Pharma seller in Q2 2020 was Baker Bros. Advisors, an estimated $12M sold.
Based on aggregated 13F filings for Q2 2020.